with high affinity to the α 2 δ subunit of voltage-gated calcium channels and exerts analgesic, anxiolytic, and antiseizure activities. Two-year carcinogenicity studies were completed in B6C3F1 and CD-1 mice and two separate studies in Wistar rats. Doses in mice were 200, 1000, and 5000 mg/kg/day, with systemic exposures (AUC 0-24 h ) up to 31 times the mean exposure in humans, given the maximum recommended clinical dose. In rats, doses were 50, 150, and 450 mg/kg/day in males and 100, 300, and 900 mg/kg/day in females; systemic exposures up to 24 times were achieved in clinical trials. In both strains of mice, pregabalin treatment was associated with an increased incidence of hemangiosarcoma primarily in liver, spleen, and bone marrow. The incidence of hemangiosarcoma was higher in B6C3F1 mice than in CD-1 mice, consistent with its spontaneous incidence. Pregabalin did not increase the incidence of any other tumor type in rats and was not genotoxic, based on an extensive battery of in vivo and in vitro tests in bacterial and mammalian systems. Thus, pregabalin is a single-species, single tumor-type, nongenotoxic mouse carcinogen. Hemangiosarcomas occurring in mice treated with pregabalin were genotypically distinct from hemangiosarcomas induced by genotoxic carcinogens in humans with respect to ras and p53 mutation patterns and were similar to spontaneous tumors. Furthermore, there was a strong association between pregabalin treatment and bone marrow changes in these studies in mice, suggesting a possible link between the effects observed in bone marrow and the increase in tumor incidence in pregabalin-treated mice.
Pregabalin has been demonstrated to be efficacious in the treatment of peripheral and central neuropathic pain in adults (diabetic peripheral neuropathy [DPN] , postherpetic neuralgia [PHN] , and spinal cord injury), in the treatment of generalized anxiety disorder, and as an adjunctive therapy for patients with partial onset seizures, with or without secondary generalization. In the United States, it has been approved for the treatment of DPN and PHN, as well as the adjunctive treatment of partial-onset epilepsy and fibromyalgia. Pregabalin binds with high affinity to the α 2 δ subunit of voltage-gated calcium channels, and the analgesic, antiseizure, and anxiolytic activities of pregabalin are related to binding affinity at that site, though the precise mechanism of efficacy is not known (Dooley et al., 2007; Field et al., 2006; Taylor, 2004; Taylor et al., 2007) .
Structurally, pregabalin is related to the endogenous amino acid L-leucine and to the naturally occurring inhibitory neurotransmitter γ-aminobutyric acid (GABA) (Fig. 1) . However, pregabalin is not active at GABA A , GABA B , or benzodiazepine receptors, and it does not alter GABA degradation or acutely change GABA uptake in brain tissue (Zareba, 2005) .
Pregabalin undergoes minimal metabolism in most species, including humans, and has a wide tissue distribution, with concentrations in most tissues similar to that in blood. Renal excretion is the primary route of elimination. Analysis of pregabalin for structural alerts using the in silico predictive systems DEREK and CASE/Multicase suggests that pregabalin contains no biologically relevant molecular features associated with genotoxicity or carcinogenicity (S. K. Duddy, unpublished data) .
Based on tolerance and efficacy in clinical trials, it has been found that the maximum recommended clinical dose of pregabalin is 600 mg/day. Systemic exposures (AUC 0-24h ) associated with this dose are approximately 123 μg h/ml and form the basis for calculation of multiples of human exposure presented in this article.
Pregabalin is intended for treatment of chronic conditions, necessitating an assessment of genotoxicity and carcinogenic potential. Herein, we describe the results of analyses that indicate that pregabalin does not have genotoxic potential but selectively increases the incidence of hemangiosarcomas in mice in 104-week carcinogenicity studies. Two separate mouse carcinogenicity studies were conducted to evaluate the possible role of the differences in the incidence of spontaneous hemangiosarcomas between B6C3F1 and CD-1 mice. Tumor incidence was not increased in carcinogenicity studies in rats. A second rat carcinogenicity study was also conducted, which confirmed the initial negative findings. Additionally, we summarize the analysis of ras and p53 alterations in the mouse hemangiosarcomas, which suggests that the mouse tumors are genetically distinct from human hemangiosarcoma.
MATERIALS AND METHODS

Test Substance
Pregabalin is chemically described as (S)-3-(aminomethyl)-5-methylhexanoic acid with a molecular weight of 159.23. Pregabalin used in these studies was > 99% active and was homogeneous and stable in aqueous vehicles used in the genotoxicity studies and when blended with powdered rodent chow for the rodent carcinogenicity studies. Concentrations in dosing/ exposure preparations were confirmed by chemical analysis, and pregabalin retained potency over the duration of studies.
Genotoxicity Studies
Genotoxicity studies using standard methodology compliant with U.S. Food and Drug Administration (FDA) and Organization for Economic Cooperation and Development guidelines were conducted at Pfizer (Ann Arbor, MI) or Covance Laboratories (Vienna, VA or North Yorkshire, U.K.) between 1993 and 2001. Evaluation of genotoxicity was based on assays for bacterial mutagenicity, structural chromosomal aberrations (SCA), in vitro mammalian cell mutagenicity, in vivo micronucleus (MN) in Wistar rats, and unscheduled DNA synthesis (UDS) in B6C3F1 and CD1 mice.
Rodent Carcinogenicity Studies
Rodent carcinogenicity studies were conducted at MPI Research (MPI; Mattawan, MI) between 1997 and 2000 (B6C3F1 mouse and Wistar rat), Centre International de Toxicologie (CIT; Evreux, France) between 2000 and 2002 (CD-1 mouse), and MDS Pharma Services (MDS; l'Arbresle, France) between 1998 and 2000 (Wistar rat). All studies were conducted in compliance with FDA Good Laboratory Practice Regulations. Animal use was in accordance with the Guide for the Care and Use of Laboratory Animals (The National Academies Press, Washington, DC, Eighth Edition, 2011). Animals were randomized into study groups using a block randomization procedure in which the animals were stratified by body weight according to the Xybion randomization procedure.
Homogeneity of the group by weight was used as the acceptance criterion of the randomization. At the time of allocation to study groups, the weight variation of animals did not exceed ± 20% of the mean weight for the respective sex.
Pretest health screens were also conducted on five male and five female animals that were randomly selected. Animals were necropsied, and a gross macroscopic examination was conducted. In addition, serological screening for common rodent pathogens was assessed.
Mouse carcinogenicity. Random-bred, barrier-raised B6C3F1:CrlBR and CD 1 Crl:CD-1(ICR)BR mice were obtained from Charles River Laboratories, Portage, MI, and l'Arbresle, France, respectively. The mice were approximately 6 weeks old at study initiation, with males weighing 17-21 g and females 14-18 g (B6C3F1) or 22-32 g and 16-27 g, respectively (CD-1). Animals were individually housed in stainless steel wire-mesh cages (B6C3F1) or polycarbonate cages on autoclaved sawdust (CD-1) in environmentally controlled rooms with a 12-h light/12-h dark cycle, a humidity range of 44-75% (MPI) or 50 ± 20% (CIT), and a temperature range of 18°C-27°C (MPI) or 21°C ± 2°C (CIT). Water and Certified Rodent Chow no. 5002 (Purina Mills, Inc., St Louis, MO; MPI) or A04 C powdered maintenance diet (UAR, Villemoisson, Epinaysur-Orge, France; CIT) were available ad libitum.
Experimental design. In this study, 65 mice per sex per group were given pregabalin in diet at 0 (untreated control), 200, 1000, or 5000 mg/kg/day for 2 years. Test article:dietary mixtures were prepared weekly at concentrations to achieve the targeted dose levels based on the mean body weight and food consumption values in the previous week. Pharmacokinetic and toxicity studies of up to 13-week duration at doses up to 8000 mg/kg revealed no dose-limiting toxicity in either strain of mice. Thus, the highest dose, 5000 mg/kg, was selected to achieve an area under curve (AUC) (0-24) value at least 25 times the anticipated human exposure at the maximum therapeutic dose (~123 μg h/ml; 600 mg) in accordance with ICH guidelines for nongenotoxic pharmaceuticals. The low and mid doses (200 and 1000 mg/kg, respectively) were selected to achieve a fivefold separation of doses and were expected to result in AUC (0-24) values equivalent to and approximately 5 times the human systemic exposure.
Animals were observed daily for clinical signs of toxicity, and detailed physical examinations were conducted weekly. Individual body weights were recorded weekly through week 13 and once per month for the duration of the study. Individual food consumption was recorded weekly. Ophthalmoscopic examinations were conducted at approximately 6-month intervals. Hematology evaluations were conducted on surviving animals at study termination, except for those mice used for plasma drug concentration analysis. The following hematology parameters were measured: red blood cells, hemoglobin, mean cell volume, packed cell volume, mean cell hemoglobin concentration, mean cell hemoglobin, red cell distribution width, platelets, mean platelet volume, leucocytes, differential white cell count with cell morphology (neutrophils, eosinophils, lymphocytes, and monocytes), and reticulocytes.
Plasma samples for drug concentration analysis (Cmax) were obtained 4 h into the dark cycle from the first 5 surviving mice/sex/group during week 104. Pharmacokinetic (PK) parameters were calculated using a model-independent approach as described by Gibaldi and Perrier (1982) . The area under the plasma concentration-time curve (AUC0-τ, where τ is the dosing interval) was calculated using the linear trapezoidal rule. AUC (0-24 h) values were calculated from 4-week studies and had similar Cmax values as those collected from week 104 from the carcinogenicity studies. The exposure multiples were calculated using the mean exposure in humans at 600 mg, the highest clinical daily dose (AUC [0-24 h] = 122 μg h/ml).
Histopathology and statistical analysis. Mice were euthanized by carbon dioxide inhalation. Complete postmortem examinations were performed on all mice. At necropsy, the following organs were weighed: brain, heart, liver, spleen, kidney, testes, ovaries, prostate, and uterus. Representative samples of organs, tissues, all masses, and all gross lesions were collected and processed for microscopic examination.
Tissues from all animals were examined microscopically by study pathologists at MPI (B6C3F1) or at Experimental Pathology Services AG, Muttenz, Switzerland (CD-1) using established diagnostic criteria. Tumor diagnoses were peer-reviewed. Diagnostic discrepancies were re-examined blindly by Pfizer and independent consulting pathologists, and consensus tumor diagnoses were compiled for statistical analysis.
The presence of helicobacter in hemangiosarcoma specimens was assessed using the following methods. Hematoxylin and eosin-stained histologic sections were prepared from frozen hemangiosarcoma specimens and from fixed, paraffin-embedded hemangiosarcoma and normal liver tissue samples. A total of 45 tumor samples were analyzed from the control (1M, 1F), 200-(1F), 1000-(5F, 4M), and 5000 mg/kg (13F, 20M) dose groups. Forty of the 45 samples were liver hemangiosarcomas, and the remaining 5 were hemangiosarcoma of the spleen (2), skin (2), and uterus (1), which were selected as negative control tumors because these tissues are not targets for H. hepaticus infection. In five cases, both frozen and paraffin sections of a tumor were analyzed. A total of 33 specimens of liver tissue adjacent to liver hemangiosarcoma were analyzed from the control (2F, 1M) and 5000 mg/kg (13F, 17M) dose groups. Tumor cells or normal liver samples were identified microscopically and dissected from histologic sections by laser capture microdissection (LCM). DNA was extracted from the LCM samples, the DNA lysates were processed by primer extension preamplification (PEP) to amplify the whole genome, and the PEP products were purified. Aliquots of PEP product were analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis for the presence of H. hepaticus DNA.
For quantitative analysis of nonneoplastic parameters in B6C3F1 mice, Levene's test was used to assess homogeneity of variances (Milliken and Johnson, 1992 (Dunnett, 1964; Welch, 1937) . In CD-1 mice, the Kolmogorov-Lilliefors test (p < 0.01) was used to assess normality of the distribution of data (Lilliefors, 1967) . If data were normally distributed, Bartlett's test (p < 0.01) (Bartlett, 1937) was used to assess homogeneity of variance, and based on the outcome, each treatment group was compared with controls using either Dunn's test (p < 0.01) (Dunn, 1964 ) or Dunnett's t-test (p < 0.01) (Dunnett, 1955) .
The survival percentage for each group was estimated by the product-limit method (Kaplan and Maier, 1958) . Pairwise differences between each dose group and control were assessed using logrank tests, as described by Tarone and Ware (1977) . A test for dose-response trend was also performed (Tarone, 1975) . These tests were two tailed at the 5% significance level.
Assessment of mouse carcinogenic potential was based on differences in tumor incidence between drug-treated and control groups. Each tumor category was analyzed using the Peto dose trend test (Peto et al., 1980) , according to the methods described by Lin and Ali (1994) . The levels of significance used for all tests were 0.005 for common tumors and 0.025 for rare tumors, one-tailed. Rare tumors are defined as tumors occurring in 1% or less of the concurrent controls. The Peto method was used as the primary method of tumor analysis for tumors found in more than 12 animals across all groups of the same sex. For the analysis of tumors observed in 12 or fewer animals across all groups of the same sex, the exact trend test according to Ali (1990) was used. The incidence of hemangiosarcomas in males was also compared with that in the corresponding controls through pairwise comparisons using Peto's test.
Rat carcinogenicity. Random-bred, barrier-raised Crl: (WI) BR VAF/Plus (Wistar) rats were obtained from Charles River Laboratories, Kingston, NY. Rats were approximately 8 weeks old, with males weighing 211-238 g and females weighing 154-176 g (MPI), or 7 weeks old at study initiation, with males weighing 192-270 g and females weighing 141-209 g (MDS). Animals were individually housed in stainless steel wire-mesh cages in environmentally controlled rooms with a 12-h light/12-h dark cycle, a humidity range of 42-76% (MPI) or 55 ± 15% (MDS), and a temperature range of 18°C-24°C (MPI) or 22°C ± 2°C (MDS). Water and Certified Rodent Chow no. 5002 (Purina Mills; MPI) or A04 powdered maintenance diet (UAR; MDS) were available ad libitum.
Experimental design. In this study, 65 rats per sex per group were given pregabalin in diet at 0 (untreated control), 50, 150, or 450 mg/kg/day in males and 0, 100, 300, or 900 mg/kg/day in females for 2 years. Test article:dietary mixtures were prepared weekly at concentrations to achieve the targeted dose levels based on the mean body weight and food consumption values in the previous week. High doses of 450 and 900 mg/kg in males and females, respectively, were selected based on the maximum tolerated doses determined in studies of 13-and 52-week duration. Body weight gain suppression was 25 and 45% in males at 500 and 1250 mg/kg, respectively, and 42% in females at 1250 mg/kg after 13 weeks of pregabalin treatment. In the 52-week study, hematologic changes, bone marrow hypocellularity, and urinary bladder lesions o ccurred with higher incidence at ≥ 250 mg/kg. Survival was not affected in either of these studies. Hence, high doses of 450 and 900 mg/kg in males and females, respectively, were selected primarily based on the body weight changes in these studies. The low and mid doses were selected based on human therapeutic exposure multiples.
Experimental procedures used to conduct the rat studies were identical to those described for mice, with the exception that the plasma samples for drug concentration analysis were obtained 7 h into the dark cycle rather than 4 h as in mice, and a more extensive organ weight list was used. For rats, the following organs were weighed: brain, heart, liver, submanidular salivary, spleen, kidneys, adrenal glands, pituitary, testes, prostate, uterus, ovaries, and epididymides. The following hematology parameters were measured: red blood cells, hemoglobin, hematocrit, mean cell volume, packed cell volume, mean cell hemoglobin concentration, mean cell hemoglobin, red cell distribution width, platelets, mean platelet volume, leucocytes, differential white cell count with cell morphology (neutrophils, eosinophils, lymphocytes, and monocytes), and reticulocytes. Both the mouse and rat carcinogenicity studies were conducted sequentially. The rationale for repeating these studies was to confirm the hemangiosarcoma findings in a second strain of mouse and to provide samples for the mechanistic studies described in the companion articles.
Histopathology and statistical analysis. Methods for postmortem analysis were identical to those described above for mice, except for the quantitative analysis of nonneoplastic parameters in the MDS study, where Levene's test was used to assess equality of variances and Shapiro-Wilk's test was used to assess normality of the distribution of data (p < 0.01) (Bolton, 1984; Shapiro and Wilk, 1965) . Normally distributed data were analyzed by one-way ANOVA, allowing for a group effect, followed, if the ANOVA test was significant, by Student's test (pretreatment data) or Dunnett's test to assess the significance of any differences between treated and control groups (p < 0.01). Data showing nonhomogeneous variances across groups or a nonnormal distribution in at least one group were analyzed using nonparametric methods. Such analysis consisted of the Kruskal-Wallis test, followed by the Wilcoxon rank sum test if the Kruskal-Wallis test was significant (p < 0.01) (Bolton, 1984; Dunnett, 1964; Milliken and Johnson, 1992; Shapiro and Wilk, 1965) .
Tumor Genotyping-p53 and ras Gene Mutations in B6C3F1 Mouse Hemangiosarcomas
Hematoxylin and eosin-stained histologic sections without coverslips were prepared from frozen and fixed, paraffin-embedded hemangiosarcoma samples from the MPI mouse carcinogenicity study. Sections were prepared from all tissues identified as containing hemangiosarcoma, a total of 198 tumors from 99 animals. Of the 198 sections screened for the presence of hemangiosarcoma, sufficient numbers of tumor cells for analysis (> 250) were obtained from 174 hemangiosarcomas. Tumor cells were isolated by LCM. DNA was extracted, the lysates were processed by PEP, and the PEP products were purified (Duddy et al., 1999a) . Aliquots of PEP products were analyzed for mutations in the Haand Ki-ras oncogenes and the p53 tumor suppressor gene by PCR and DNA sequencing (Duddy et al., 1999b,c) . Table 1 summarizes the genetic toxicity analyses conducted with pregabalin, which were negative for all endpoints.
RESULTS
Genotoxicity Studies
Pregabalin was not mutagenic in bacteria up to the maximum dose of 5000 µg/plate, with or without metabolic activation. Metabolic activation was assessed using S9 from B6C3F1, CD-1 mice, and Sprague Dawley rats. In mammalian cells (Chinese hamster ovary) in vitro, no evidence of point mutations or SCA was observed up to the maximum concentration of 1600 µg/ ml, with or without metabolic activation. Pregabalin did not induce UDS in hepatocytes of B6C3F1 or CD-1 mice or Wistar rats given single oral doses up to the maximum dose of 2000 mg/kg. MN frequency was not increased in bone marrow from B6C3F1 or CD-1 mice or Wistar rats given single oral doses of pregabalin up to the maximum dose of 2000 mg/kg ( Table 1) .
Mouse Carcinogenicity Studies
Clinical and hematologic effects. Clinical and hematologic effects of pregabalin were similar in the B6C3F1 and CD-1 mouse carcinogenicity studies. An increased incidence of distended abdomens and anogenital staining was observed late in the studies, primarily at the mid and high doses (data not shown). There was no macroscopic or microscopic correlate for the finding of distended abdomens, but the anogenital staining correlated with urinary bladder dilatation. Nondose-related increases in body weights (relative to controls) occurred within several weeks of dosing initiation and persisted to study termination. Increases ranged from 15 to 31% in B6C3F1-treated groups and from 5 to 21% in treated CD-1 mice. A dose-related increase in food consumption was observed in all treated groups of both strains that persisted for most mice of each study. In B6C3F1 mice, increases ranged approximately 6-9% in males and 5-11% in females. In CD-1 mice, increases ranged 4-5% in males and 4-9% in females.
At termination, platelet counts were increased 32-58% relative to that of controls in B6C3F1 males at 1000 and 5000 mg/kg/day and in females at all dose levels. In CD-1 mice, platelet counts were increased in males given 5000 mg/kg/ day, and although not statistically significant, there was a trend toward increased counts in females given 5000 mg/kg/day ( Table 2 ). The platelet changes correlated with an increased incidence of splenic extramedullary hematopoiesis (see the Nonneoplastic Pathology section). In contrast, RBC was decreased in B6C3F1 and CD-1 males (89-92% relative to that of controls) but was unchanged in females of both strains.
Toxicokinetics. After 2 years of dosing, plasma concentrations of pregabalin in B6C3F1 mice determined at a single sampling point chosen to approximate peak daily concentrations (4 h into the dark cycle) at 200, 1000, and 5000 mg/kg/ day were 4.55, 21.5, and 98.8 µg/ml in males and 5.83, 48.0, and 139 µg/ml in females. These results were comparable to Cmax values determined in a supportive 4-week duration study at 200, 1000, and 5000 mg/kg/day of 10.9, 50.6, and 215 µg/ml in males and 9.06, 42.6, and 209 µg/ml in females, respectively (data not shown). Based on the 4-week study, AUC exposure multiples of approximately 1, 6, and 31 were achieved at doses of 200, 1000, and 5000 mg/kg, respectively, relative to those of projected human clinical exposure at the maximum daily dose of 600 mg (122 µg h/ml) ( Fig. 2A) .
In CD-1 mice, plasma concentrations determined after 2 years of dosing at 200, 1000, and 5000 mg/kg/day, respectively, were 14.3, 49.7, and 429 µg/ml in males and 11.0, 61.9, and 473 µg/ml in females. These results were comparable to Cmax values determined in a separate 4-week duration study at 200, 1000, and 5000 mg/kg/day, respectively, of 8.72, 42.7, and 218 µg/ml in males and 7.89, 43.5, and 174 µg/ml in females. Based on the 4-week study, AUC exposure multiples of approximately 1, 5, and 28 were achieved at doses of 200, 1000, and 5000 mg/ kg/day, respectively (Fig. 2B) .
Nonneoplastic pathology. In B6C3F1 mice at termination, absolute testes weights and testes weights relative to body weight were decreased by 20 and 32%, respectively, at 5000 mg/kg, which correlated with an increased incidence of testicular degeneration (data not shown). Absolute and relative liver weights were increased 24 and 48% in all drug-treated females, which correlated with an increased incidence of liver mass nodules observed macroscopically (data not shown). Increased splenic extramedullary hematopoiesis was observed in males at 1000 mg/kg and in both sexes at 5000 mg/kg (data not shown). Splenic extramedullary hematopoiesis may have been a change secondary to hemangiosarcomas, though causal (mechanistic) association with tumorigenesis cannot be ruled out. It may have also contributed to the increased platelet counts and enlarged spleens observed macroscopically. An increased incidence of urinary bladder dilatation was also observed in males at 5000 mg/kg, which correlated with anogenital staining. In CD-1 mice, testes weights relative to body weight were decreased 16% at 1000 and 5000 mg/kg, which again correlated with an increased incidence of testicular degeneration. In females, absolute and relative liver weights were increased 16-59% at all doses, and kidney weights were increased 20-32% at 1000 and 5000 mg/kg (data not shown). There were no histopathological correlates to the organ weight changes for the liver or kidney, but one contributing factor for the increase in absolute organ weights was that body weights were increased as much as 21% in females and 18% in males, at high dose. The incidence and severity of alveolar macrophage infiltration with associated changes (i.e., cholesterol cleft formation and perivascular, lymphoid-cell infiltration) were increased in females given 5000 mg/kg (data not shown). Alveolar macrophage infiltration was a spontaneous age-related finding in mice that was exacerbated by treatment in this instance. It was not associated with increased incidence of lung tumors and did not appear to be a cause of increased mortality in these animals.
Survival and tumor analysis.
A dose-related decrease in survival was observed in B6C3F1 males and females at 1000 and 5000 mg/kg/day (Figs. 3A and B, respectively) . Overall survival at week 104 for the control, 200, 1000, and 5000 mg/kg groups was 88, 80, 62, and 34%, respectively, in males and 69, 68, 44, and 38%, respectively, in females. Survival at week 80 was 97, 94, 80, and 73%, respectively, in males and 91, 86, 77, and 74%, respectively, in females. These data met the criteria for a valid study (> 50% survival in all groups at week 80) as defined by Lin and Ali (1994) .
Of 34 tumor types in male and 41 tumor types in female B6C3F1 mice, there were 6 tumor categories in each sex that showed a statistically significant positive dose trend in the Peto test as indicated in Table 3 . When analyzed by the exact trend test, there were no statistically significant positive dose trends for any of the tumor categories with ≤12 tumorbearing animals. The only tumor categories for which there were statistically significant positive dose trends were all tumors, all malignant tumors, and hemangiosarcomas. When hemangiosarcomas were subtracted out, the incidence of all malignant tumors was 16, 13, 17, and 6 in males and 22, 23, 21, and 10 in females at 0, 200, 1000, and 5000 mg/kg, respectively. These data demonstrate that hemangiosarcomas were the reason for the positive dose trend for all malignant tumors. When analyzed by the Fisher exact test, there was no statistically significant difference between the incidences of hemangiosarcomas in the low dose versus the controls in either sex (p = 0.485 for males; p = 0.098 for females), suggesting that 200 mg/kg was a no-effect dose for a carcinogenic response. However, a numerical increase in hemangiosarcoma incidence was observed in the low-dose female group compared with untreated controls.
The incidence of hemangiosarcoma was statistically increased in both male and female B6C3F1 mice at 1000 and 5000 mg/kg (Table 4) . Hemangiosarcomas occurred in multiple tissue/organ sites although they were most frequently observed in the liver, spleen, and bone marrow and correlated with clinical signs (internal palpable masses) and macroscopic findings (liver masses and enlarged spleens). Hemangiosarcomas were considered the cause of death in 1, 3, 13, and 13 males and in 1, 3, 12, and 15 females at 0, 200, 1000, and 5000 mg/kg, respectively. The first hemangiosarcoma was diagnosed in a control female found dead in week 49. The first hemangiosarcoma in a drug-treated group occurred in a 1000 mg/kg male during week 50.
The results in CD-1 mice were similar though the overall incidence of hemangiosarcoma was reduced. Survival data are presented in Figures 3C and D , and tumor incidence is given in Table 4 . There was a statistically significant difference in males at the 5000 mg/kg dose level when compared with untreated controls (p < 0.005). In females, there was a slight increase in tumor incidence with dose, but the dose trend was not statistically significant (p = 0.0058). Hemangiosarcomas occurred in multiple tissues of both males and females but were found most frequently in the liver, spleen, bone marrow, and uterus. There were no other tumor types that were statistically increased.
Rat Carcinogenicity Studies
Clinical and hematologic effects. Results were similar in the studies conducted at MPI and MDS. Urine staining was observed related to pregabalin dosing, but there were no other test article-related clinical signs. Body weight and food consumption at 450 mg/kg/day in males and 900 mg/ kg/day in females were consistently decreased compared with those in controls throughout the studies. Body weight gain was decreased 22% in males and 40-41% in females of both studies. The average food consumption was lower than controls at 450 mg/kg/day in males and 900 mg/kg/ day in females by 9-24%. There were no significant effects on body weight, body weight gain, or feed consumption in the low-and mid-dose groups for these two studies.
Mild hematological changes were seen at 2 years, primarily at the mid-and high-dose levels in both sexes. Increased erythrocyte counts (5-18%) and platelet counts (12-30%) were observed (Table 2) .
Toxicokinetics. Pregabalin exposure was comparable in both studies. Group mean plasma concentrations achieved after 2 years of compound administration in the MPI study were 9.08, 24.2, and 129 µg/ml in males at 50, 150, and 450 mg/kg/day, respectively, and were 21.8, 84.1, and 193 µg/ml in females at 100, 300, and 900 mg/kg/day, respectively. Plasma concentrations in the MDS study were 15.9, 39.1, and 152 µg/ml in males and 27.7, 95.3, and 222 µg/ml in females. These results confirmed a dose-related increase in systemic exposure in both sexes. Based on supportive toxicokinetic data, in males, exposures at these dose levels were approximately 1.3, 5, and 14 times the human exposure at the maximum clinical doses of 600 mg daily (123 µg h/ml), and in females, exposures were 2.5, 8, and 24 times the estimated human exposure (Fig. 4) .
Nonneoplastic pathology. In the MPI study, the incidence of small testes was increased in all treated groups, and there were statistically significant decreases in absolute and relative epididymal and testicular weights (14-18%) at 450 mg/ kg/day. Reduced size of the testes was correlated with an increased incidence of tubular atrophy and aspermatogenesis in all treated groups. Reduced weight of the epididymides was correlated with a dose-related increase in the incidence of aspermia. The incidence of small seminal vesicles was increased at 450 mg/kg/day, but seminal vesicles were histologically unremarkable. In females, distended uterine horns were observed at 900 mg/kg/day, associated with a statistically significant increase in the mean uterus/cervix/body weight ratio (63%). The increase in uterine weights correlated macroscopically with an increased incidence of distended uterine horns with fluid (3/65, 5/65, 5/65, and 24/65 for the control, 100, 300, and 900 mg/kg/day groups, respectively). Microscopic examination demonstrated that the uterine horn dilatation was secondary to intrauterine hemorrhage of unknown origin and that there was no evidence of uterine neoplasia. An increased incidence of bilateral retinal atrophy occurred in females at 300 and 900 mg/kg/day. This lesion, commonly observed in aged rats, was considered an exacerbation of a spontaneous age-related lesion.
In the MDS study, testes weights were maintained, and there was a decreased incidence of pituitary and subcutaneous masses in treated animals, especially males at 450 mg/kg and females at 300 and 900 mg/kg. Corneal inflammation and inflammation combined with retinal atrophy and mineralization were observed in males given 150 and 450 mg/kg. Retinal atrophy was observed in females at 300 and 900 mg/kg. Marginally elevated incidence of angiectasis of the adrenal cortex was observed in males at all doses. In females, there was a marginally elevated incidence of atrophy of the ovary at 900 mg/kg and increased incidence of uterine dilatation and inflammation at 300 and 900 mg/kg.
Survival and tumor analysis. In the MPI study, survival of the treated rats was similar to that of controls. At week 104, overall survival in males was 49, 45, 51, and 65%, respectively, for the control, 50, 150, and 450 mg/kg/day groups and in females was 54, 74, 82, and 69%, respectively, for the control, 100, 300, and 900 mg/kg/day groups. In the MDS study, overall survival at week 104 in males was 58, 58, 71, and 69%, respectively. In females, survival was 52, 55, 74, and 51%, respectively. There was no statistically significant dose trend in mortality.
Most tumor categories flagged in the Peto analysis showed a negative dose trend (i.e., decreased tumor incidence with increasing dose). Four rare tumor types (two in each study)-meningioma of brain (males), squamous cell carcinoma of skin (females), granular cell tumor of brain (males), and schwannoma of heart (males)-were identified as having a positive dose trend by the Peto analysis. However, the exact trend test using the Haseman rule indicated no statistically significant positive Tumors that were not positive in the Peto test for trend with dose are not reported; none of these were significant using the Haseman's rule for common or rare tumors. Hence, the "All tumors" category will not match the number of tumors reported in this table. There were no mutations in the Ha-and Ki-ras genes and a low incidence (8%) of p53 gene mutations in tumors from the pregabalin carcinogenicity study in B6C3F1 mice (14 affected tumors out of a total of 174 tumors evaluated). There were no consistent patterns of mutation with respect to target tissue. A total of 18 p53 mutations were detected in the 14 affected tumors; however, 2 of the 14 tumors had only silent mutations (i.e., mutations that would not alter p53 protein structure or function). Therefore, the incidence of mutational inactivation of p53 in hemangiosarcomas from the B6C3F1 carcinogenicity study was 7% (12/174). All but two of the mutations (16/18; 89%) consisted of guanine to adenine (G → A), thymine to cytosine (T → C), and cytosine to thymine (C → T) transitions in the coding strand (Table 5) .
Fifteen of the 18 p53 mutations were clustered in exon 5 of the gene. The majority of exon 5 mutations (13/15; 87%) occurred in a gene sequence that is significantly divergent between mice and humans, located between evolutionarily conserved regions II and III in the DNA-binding domain of the gene. Although the remaining two exon 5 mutations occurred within conserved region III, they were silent mutations that do not alter p53 function, as were two of the three mutations located outside exon 5. There was only a single inactivating mutation present in a region of the DNA-binding domain that is conserved between mouse and human (region IV in exon 7) in the 174 hemangiosarcomas evaluated (Fig. 5) .
dose trend for these rare tumor types. In addition to this lack of statistical significance, the incidence of these rare tumors was within the spontaneous incidence range reported in the scientific literature (Poteracki and Walsh, 1998) .
Analysis of p53 and ras Gene Mutations
Definitive sequences for evaluation of p53 and ras mutations were generated from ≥ 84% of the tumors evaluated for each of the 8 loci examined, and 109 of the 174 tumors (63%) yielded definitive sequence for all 8 loci. Overall, 92% of
DISCUSSION
Pregabalin treatment was associated with an increased incidence of hemangiosarcoma in B6C3F1 and CD-1 mice, but it did not increase the incidence of any tumor type in two studies conducted in Wistar rats and was not genotoxic in any of the in vitro or in vivo mouse or rat systems tested. Further, metabolic activation in the in vitro assays using liver S9 from rats and B6C3F1 and CD-1 mice did not generate genotoxic metabolites. Metabolism of pregabalin in humans is essentially identical to that in rodents, though humans produce less of the primary metabolite, the N-methyl-derivative (≤ 0.9% in humans vs. 2-3% in rodents) (Randinitis et al., 2003; Zareba, 2005) . These results established that pregabalin was not genotoxic; therefore, the differential tumor response between mice and rats was not due to differential genotoxicity of pregabalin or its metabolites, and the increased incidence of hemangiosarcoma uniquely associated with chronic pregabalin treatment in mice occurred via an indirect, nongenotoxic mode of action.
Though hemangiosarcoma incidence was increased by treatment in both strains of mice, a differential sensitivity to tumorigenesis was observed. Hemangiosarcoma prevalence was higher in the B6C3F1 study and was statistically significant in both males and females, occurring at incidences of 10-30% at exposure multiples ranging from 5-to 31-fold exposure in humans at the maximum clinical dose of 600 mg. In CD-1 mice, a statistically significant increase in hemangiosarcoma was seen only in high-dose males at an exposure multiple of 28. This differential response to chronic pregabalin treatment between the two mouse strains was consistent with the generally lower incidence of spontaneously occurring hemangiosarcoma in CD-1 mice, typically ≤ 2%, though individual studies in both mouse strains have had background incidences of hemangiosarcoma as high as 13% (Giknis and Clifford, 2005; Haseman et al., 1988) . Additionally, pregabalin did not alter the tissue distribution, onset, or latency of hemangiosarcoma compared with spontaneously occurring hemangiosarcomas in concurrent controls of either mouse strain. The primary tissues affected in both control and treated mice were liver, spleen, and bone marrow, which historically were the most prevalent sites of spontaneous hemangiosarcoma development in B6C3F1 and CD-1 mice (Chandra and Frith, 1992a,b; Giknis and Clifford, 2005; Haseman et al., 1988) . These results were consistent with the hypothesis that pregabalin induces hemangiosarcomas in mice via a nongenotoxic mechanism.
Hemangiosarcoma is a malignant tumor of endothelial cells that is rare in humans, accounting for less than 1% of all sarcomas. Histopathologically, hemangiosarcoma in rodents is similar to cases seen in humans; however, the tumor differs significantly between humans and rodents in both tissue distribution and incidence. In the 12 regions covered by the US National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database, the incidence rate of hemangiosarcoma between 1996 and 2000 was 0.21 new cases per 100,000 people (0.00021%) (US National Cancer Institute-SEER Database). Considering the historical background incidence of hemangiosarcoma in B6C3F1 and CD-1 mice relative to the incidence rate in humans, the mouse models used to assess pregabalin effects are greater than 10,000-fold more susceptible to spontaneous development of hemangiosarcoma than are people. Hemangiosarcoma in humans arises most commonly in skin on the head and neck of elderly individuals (Weiss et al., 2001) . Distant metastasis may occur involving primarily the liver and the lung, though primary liver hemangiosarcoma has been linked to exposure to genotoxic carcinogens such as Thorotrast and vinyl chloride (Duddy et al., 1999b; Kielhorn et al., 2000; Popper et al., 1978; Przygodzki et al., 1997) . In contrast to humans, hemangiosarcoma occurs spontaneously at high incidence in liver, spleen, bone marrow and to a lesser extent in lymph nodes and skin in rodents (Chandra and Frith, 1992a,b; Giknis and Clifford, 2005; Haseman et al., 1988) .
We are aware of only two examples of hemangiosarcoma induction by a common chemical stimulus in both humans and rodents. Both examples are genotoxic carcinogens (vinyl halides and Thorotrast), and both produce primary liver hemangiosarcoma (Boivin-Angèle et al., 2000; Lipshutz et al., 2002) . The only known example of a nongenotoxic stimulus that leads to hemangiosarcoma in mice is chronic liver inflammation (hepatitis) in mice infected with Helicobacter hepaticus, which induces hemangiosarcoma with reasonably high frequency and induces a lower incidence of hepatocellular carcinoma (Hailey et al., 1998) . There was no evidence of H. hepaticus infection in the B6C3F1 carcinogenicity study. Chronic hepatitis infections and alcohol-induced liver disease in humans were linked to hepatocellular carcinoma development but not to hemangiosarcoma (Monto and Wright, 2001; Roberts and Gores, 2005) . Thus, chronic hepatitis, which has been demonstrated The exposure multiples were based on toxicokinetic studies, where AUC (0-24h) values were used to calculate human exposure multiples. In the B6C3F1 study, AUC (0-24h) values were 140, 802, and 3840 µg h/ml in female mice and 153, 653, and 3840 µg h/ml in male mice at 200, 1000, and 5000 mg/kg, respectively. In the CD-1 study, AUC (0-24h) values were 115, 558, and 3150 µg h/ml in female mice and 105, 541, and 3440 µg h/ml in male mice at 200, 1000, and 5000 mg/kg, respectively. The exposure multiples were calculated using the mean exposure in humans at 600 mg, the highest clinical daily dose (122 µg h/ml).
to promote nongenotoxic transformation of endothelial cells in mice, does not do so in humans. Mouse liver endothelial cells, therefore, appear to be much more susceptible to transformation under conditions of chronic inflammation than human liver endothelial cells, which is consistent with the vastly different rates of spontaneous hemangiosarcoma incidence between the two species.
Carcinogenesis, whether induced by genotoxic agents or nongenotoxic mechanisms, is a disease of accumulated genetic alterations leading to dysregulation of cell proliferation, and human cells are inherently more resistant to neoplastic transformation than rodent cells (Hanahan and Weinberg, 2000) . To elucidate potential similarities and differences between mouse and human hemangiosarcomas in their molecular etiology, genes that are known to be altered in human hemangiosarcomas were analyzed in the mouse tumors to determine if similar genetic changes, and thus similar pathways of growth dysregulation, were present. Activating mutations in ras proto-oncogenes and inactivating mutations in the p53 tumor suppressor gene were known to occur at frequencies of 50% or more in human hemangiosarcomas induced by chemical carcinogens (Duddy et al., 1999b,c) . p53 and ras mutation frequencies of up to 50% have also been detected in spontaneously arising human hemangiosarcomas (Duddy et al., 1999b; Przygodzki et al., 1997 ). An extensive compilation of p53 mutations identified in human hemangiosarcoma, whether carcinogen-induced or spontaneous, indicates that mutations are restricted to exons 5-8 of the gene (Béroud and Soussi, 2003) . These exons encode critical elements of the DNA-binding domain of the p53 protein that control its tumor suppressor function. Based on these findings, which suggest that ras and p53 disruption are causally associated with spontaneous and genotoxicant-induced hemangiosarcoma development in humans, it was hypothesized that significant frequencies of mutations in ras and p53 would be present in the mouse hemangiosarcomas if these genes were mechanistically linked to vascular tumorigenesis. For example, if ras and p53 gene mutations were present in the 174 mouse hemangiosarcomas identified in the current study at frequencies comparable to what have been observed in human hemangiosarcomas, as many as 87 tumors would be expected to harbor mutations in at least one of the genes. In contrast, none of the mouse tumors bore Ha-or Ki-ras gene mutations, and only 12 tumors (7%) had inactivating p53 gene mutations. In human hemangiosarcoma, p53 mutations cluster predominately within highly conserved regions II, III, IV, and V (Fig. 5) , which yield protein sequences that are ~93% identical to mouse p53. In hemangiosarcomas from the pregabalin carcinogenicity study, 11 of the 12 inactivating p53 mutations were located in a subregion of p53 exon 5 that is highly divergent between mice and humans, and only a single inactivating mutation occurred in a highly conserved region of the gene. Collectively, these data indicate that hemangiosarcomas arising in pregabalin-treated mice are genetically dissimilar to human hemangiosarcomas with respect to involvement of mutagenesis of ras and p53, and key genetic changes driving hemangiosarcoma formation in humans do not contribute significantly to tumor development in pregabalin-treated mice.
The absence of ras mutations and low incidence of p53 inactivation in the current study are similar to previous findings in spontaneous hemangiosarcomas from this mouse strain (Candrian et al., 1991; Duddy et al., 1999b,c) . Of 22 spontaneous hemangiosarcomas identified in a total of 20 vehicle and placebo control B6C3F1 mice, only a single Ha-ras mutation was identified (Duddy et al., 1999c) , and p53 inactivation was not detected, though the primary p53 screening method was immunohistochemical detection of p53 overexpression as a marker of inactivation, which is less definitive than gene sequencing (Duddy et al., 1999b) . In contrast, known genotoxic carcinogens that produce hemangiosarcoma in mice, such as butadiene, o-nitrotoluene, and riddelliine, induce mutations in ras and p53 genes at frequencies comparable to those observed in humans, up to 82% (Hong et al., 2000 (Hong et al., , 2003 . Thus, the lack of mutations in ras and low frequency of p53 inactivation in the current study are consistent with hemangiosarcomas arising due to exacerbation of endogenous mechanism(s) of spontaneous endothelial cell transformation. Additionally, the few mouse p53 mutations detected were primarily G → A, T → C, and C → T transitions, which are characteristic of mutagenesis arising from endogenous oxidative DNA damage. For instance, oxidative deamination of purines driven by NO or oxygen radicals (Nguyen et al., 1992; Wink et al., 1991) and misrepair of 5,6-dihydroxy-5,6-dihydrothymine (thymine glycol) and 5′ hydroxyl-2′-deoxycytidine that result from oxidation of thymine and cytosine residues in DNA have been shown 
Missense mutation (disrupts p53 tumor suppressor function). b Silent mutation (no functional consequence).
c T → C missense mutations (inactivating) were detected in two codons of Exon 5 in this sample in addition to a single G → A missense mutation at a third codon.
to produce these mutation patterns (Basu et al., 1989; Cooke et al., 2003; Firestein et al., 1997; Rossman and Goncharova, 1998; Souici et al., 2000; Trukhanova et al., 1998) . That these mutations arose through endogenous mechanisms is further supported by pregabalin's lack of activity in an extensive battery of genetic toxicity assays. Thus, ras activation and p53 inactivation do not appear to play significant roles in the transformation of mouse endothelial cells in pregabalin-treated mice, and the tumors appear to arise via a nongenotoxic mechanism driven by exacerbation of endogenous oxidative mechanisms of spontaneous mutagenesis.
Stimulation of proliferation in the neoplastic target cell population is characteristic of nongenotoxic carcinogens. In the case of hemangiosarcoma, endothelial cells are the target cell type, and one possible driver of endothelial cell proliferation and vascular tumor development is angiogenic growth factors. These angiogenic factors could in turn induce proliferation of endothelial cells, leading to fixation of spontaneous mutations, growth dysregulation, clonal expansion of altered cells, and ultimately hemangiosarcoma formation. Although the elevated platelet counts in mice treated with pregabalin in the carcinogenicity study may be attributed to secondary effects of the hemangiosarcomas, the decrease in platelet counts in rats, a species with no evidence of hemangiosarcomas, was a stark contrast. Additionally, the dose-dependent increases in red blood cell counts in rats demonstrated another species-specific difference. Coupling these findings with the fact that endothelial cells and hematopoietic cells arise from the same stem cell precursor, the hemangioblast (Keller, 2001 ), a further review of hematologic effects was conducted and is reported separately. Elevated numbers and activity of bone marrow erythroblasts, macrophages, megakaryocytes, and platelets that contain a wealth of bioactive and proangiogenic products may contribute to enhanced endothelial cell proliferation observed selectively in mice treated with pregabalin. These aspects of a potential mode of action for pregabalin induction of hemangiosarcoma have been investigated and were reported in companion articles (Criswell et al., 2012 a,b) .
In 2009, a unified mode-of-action framework for induction of hemangiosarcoma by nongenotoxic compounds, including pregabalin, was proposed whereby five components appeared to be shared across the diverse compounds that induce hemangiosarcoma (Cohen et al., 2009) . Specifically, agents that induce hemangiosarcoma appear to have initiating events that lead to local tissue hypoxia and macrophage activation. These two changes increase angiogenic growth factors. This process was analogous to physiologic angiogenesis, but it was hypothesized that agents that induce hemangiosarcoma produce dysregulated angiogenesis.
In the case of pregabalin, it appears that dysregulated erythropoiesis in the mouse also contributes to this process (Criswell et al., 2012a) . In the following companion articles, we summarize the species-specific pregabalin changes that are consistent with this unified mode-of-action framework. Specifically, pregabalin induces macrophage activation and increased angiogenic growth factors in bone marrow, spleen, and liver tissues, with a high incidence of hemangiosarcomas in the mouse (Criswell et al., 2012a) . Pregabalin also increased local tissue hypoxia and endothelial cell proliferation in mouse liver (Criswell et al., 2012b) , which are hallmarks of nongenotoxic tumor formation. All of these changes were absent in the rat. Companion articles (Criswell et al., 2012 a,b,c) provide details of these speciesspecific changes and their potential relevance to the proposed mode of action of hemangiosarcoma in mice.
In conclusion, pregabalin treatment selectively increased the incidence of a single tumor type (hemangiosarcoma) via a nongenotoxic mechanism in mice, a species predisposed to development of this tumor type. Hemangiosarcomas from affected mice were genotypically distinct from their human counterparts, further suggesting a species-specific mechanism of origin.
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